132 related articles for article (PubMed ID: 10533510)
41. Leflunomide.
Cohen SB; Iqbal I
Int J Clin Pract; 2003 Mar; 57(2):115-20. PubMed ID: 12661795
[TBL] [Abstract][Full Text] [Related]
42. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
[No Abstract] [Full Text] [Related]
43. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
44. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
Bartlett RR; Brendel S; Zielinski T; Schorlemmer HU
Transplant Proc; 1996 Dec; 28(6):3074-8. PubMed ID: 8962190
[No Abstract] [Full Text] [Related]
45. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
46. Pharmaceutical agents for the treatment of rheumatoid arthritis.
Scott TE
Manag Care; 2001 Jul; 10(7 Suppl):2-9. PubMed ID: 11729431
[No Abstract] [Full Text] [Related]
47. [Methotrexate therapy in rheumatoid arthritis].
Ichikawa Y; Shinozawa T; Yoshida T; Akama H; Kameda H
Ryumachi; 1991 Oct; 31(5):544-53. PubMed ID: 1767348
[No Abstract] [Full Text] [Related]
48. Neck problems in rheumatoid arthritis--changing disease patterns, surgical treatments and patients' expectations.
Choi D; Casey AT; Crockard HA
Rheumatology (Oxford); 2006 Oct; 45(10):1183-4. PubMed ID: 16880191
[No Abstract] [Full Text] [Related]
49. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
Simon LS
Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
[TBL] [Abstract][Full Text] [Related]
50. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
Erkan D; Yazici Y; Harrison MJ; Paget SA
Arthritis Rheum; 2002 Jun; 47(3):285-90. PubMed ID: 12115159
[TBL] [Abstract][Full Text] [Related]
51. Investigational treatments in rheumatoid arthritis.
Breedveld FC
Baillieres Best Pract Res Clin Rheumatol; 1999 Dec; 13(4):701-18. PubMed ID: 10652649
[TBL] [Abstract][Full Text] [Related]
52. Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: a nationwide population-based cohort study.
Chen HH; Chen DY; Lai KL; Chen YM; Chou YJ; Chou P; Lin CH; Huang N
J Clin Rheumatol; 2013 Dec; 19(8):432-8. PubMed ID: 24263145
[TBL] [Abstract][Full Text] [Related]
53. Mechanisms of action of methotrexate.
Genestier L; Paillot R; Quemeneur L; Izeradjene K; Revillard JP
Immunopharmacology; 2000 May; 47(2-3):247-57. PubMed ID: 10878292
[No Abstract] [Full Text] [Related]
54. Mechanisms of action of slow-acting drugs in rheumatoid arthritis.
Lipsky PE
Clin Exp Rheumatol; 1989; 7 Suppl 3():S177-80. PubMed ID: 2575024
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of standard slow-acting antirheumatic drugs.
Epstein WV
Semin Arthritis Rheum; 1994 Jun; 23(6 Suppl 2):32-8. PubMed ID: 7939729
[TBL] [Abstract][Full Text] [Related]
56. Rheumatoid arthritis: anticytokine therapies on the horizon.
Koopman WJ; Moreland LW
Ann Intern Med; 1998 Feb; 128(3):231-3. PubMed ID: 9454532
[No Abstract] [Full Text] [Related]
57. Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal.
Braun J; Sieper J; van der Heijde D
Ann Rheum Dis; 2003 Oct; 62(10):1023-4. PubMed ID: 12972492
[No Abstract] [Full Text] [Related]
58. Strategies for the development of new antiarthritic agents.
Lewis AJ; Glaser KB; Sturm RJ; Molnar-Kimber KL; Bansbach CC
Int J Immunopharmacol; 1992 Apr; 14(3):497-504. PubMed ID: 1618601
[TBL] [Abstract][Full Text] [Related]
59. FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma.
Paulus HE
Arthritis Rheum; 1986 Oct; 29(10):1289-90. PubMed ID: 3768061
[No Abstract] [Full Text] [Related]
60. Advances in targeted therapies V: Proceedings of the 5th International Symposium. St Martin, French West Indies. 11-14 April 2003.
Ann Rheum Dis; 2003 Nov; 62 Suppl 2():ii1-96. PubMed ID: 14532137
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
